Page 23 of 25: studies 441 to 460 of 481, newest first. Back to the psilocybin overview
2026 Yosr Ziadi, Taehwan Park preprint
Conference poster presented at ISPOR 2026, Philadelphia, May 2026. Co-authors: Yosr Ziadi, Taehwan Park. St. John's University.
Cahiers francophones de soins palliatifs 2026 Michel Dorval, Sue-Ling Chang, Houman Farzin et al.
La psychothérapie assistée par psilocybine représente un ajout prometteur aux interventions de soins palliatifs, pouvant améliorer la qualité de vie en soulageant la détresse existentielle. Malgré sa sécurité et son efficacité, cette thérapie demeure limitée au Canada, soulignant la nécessité d’en améliorer l'accès pour atténuer la souffrance liée à des maladies potentiellement mortelles....
2026 Tom Bielen preprint
Psilocybin-assisted therapy has produced promising results in clinical trials for depression, but most existing reviews treat major depressive disorder (MDD) and treatment-resistant depression (TRD) as a single category. This conflation is a problem. MDD and TRD differ in diagnostic criteria, illness severity, prior treatment failure, and likely neurobiological profile. Pooling their results...
2026 Irina Dell'Orto preprint
Background: Psilocybin-assisted therapy (PAT) has demonstrated rapid and substantial antidepressant effects in phase 2 RCTs (Davis et al., 2021; Carhart-Harris et al., 2021), and phase 3 trials are now active (Usona uAspire, NCT06308653). However, three critical gaps remain unresolved in 2025: (1) the durability of effects beyond 12 months has not been established in a controlled design; (2)...
2026 Diego Monasterio López
Psychedelic experiences have shown promise in addressing mental health challenges (Doblin et al., 2019). Among these, ego dissolution is a central phenomenon associated with lasting therapeutic effects, involving a temporary disruption of the neurocognitive self-model that loosens entrenched patterns of rumination and self-reference (Kałużna et al., 2022; Letheby, 2021; Deane, 2020; Nour et...
2026 Canyon Akromis, Lorraine Li, Kwon Mok Ko et al. preprint
This project is a secondary analysis of data from Psilocybin in Depression Resistant to Standard Treatments (PsiDeR) study, a phase II, randomised, placebo-controlled clinical trial where participants with treatment resistant depression received either 25 mg of psilocybin or a placebo alongside psychotherapy. This research seeks to determine whether the therapeutic alliance, measured by the...
Science academique 2026 Kenneth Blum, Kai-Uwe Lewandrowski, Morgan P Lorio et al.
The aim of this perspective article is to evaluate the potential of Psychedelics in the management of Alcohol Use Disorder (AUD) vis-a-vis pre-existing therapeutic modalities and to elucidate practical directions for policy in AUD Addiction medicine, supported by scientific evidence, while prioritizing safety and accessibility. We performed a narrative synthesis of past and current literature...
Open Mind 2026 Amin Nazmuddin Mohammadi, Christine Wekerle preprint
Alcohol use disorder (AUD) is a prevalent and chronic psychiatric condition characterized by impaired control over alcohol use, compulsive consumption, and high rates of relapse (Grant et al., 2015; Kurihara, 2023). Despite the availability of pharmacological and psychosocial interventions, treatment outcomes remain suboptimal, with substantial rates of non-response and relapse (Lohoff, 2022;...
SSRN Electronic Journal 2026 Amanda Elyse preprint
Psilocybin is the primary psychoactive compound in “magic mushrooms”; it has been used by humans for millennia, it is in promising clinical trials with humans and used in legalized psilocybin-assisted therapy, and researchers use and are further developing human-based methods with cutting-edge technologies. However, researchers are still allowed to conduct unreliable and distressing psilocybin...
Journal of Music Therapy 2026 Clare O’callaghan, Voula Kallianis, Margaret Ross
Limited evidence supports treatment for distress in life-threatening illness. Psychedelic-assisted psychotherapy (PAP) may help. Despite music's presence in PAP, sparse accounts of music-related experiences exist. Such research is needed to optimize music's presence within PAP. This qualitative analysis aimed to understand participants' music-related accounts of their PAP experiences within a...
International Journal of Drug Policy 2026 Christina Chwyl, Adrianne R Wilson-Poe, Kim Hoffman et al. 3 citations
There remain significant gaps in knowledge about best practices for facilitated psychedelic care and psychedelic-assisted therapy. To inform the development of service models that support safe and beneficial experiences, this qualitative study explored expert perspectives on current and ideal standards of care, including key practices (e.g., screening, adapting care to diverse contexts) and...
Neuroscience & Biobehavioral Reviews 2026 Netta Pinhas, Nofar Eidlman, Avigail Barnea et al. 2 citations
Microdosing - the practice of consuming extremely low doses of classical psychedelic substances that do not elicit overt psychedelic effects - has gained significant attention as a potential method for enhancing cognitive performance. However, findings from controlled studies remain mixed and inconclusive. This preregistered meta-analysis examined the cognitive effects of classical psychedelic...
Journal of the Brazilian Chemical Society 2026 Mateus Araújo Da Luz, Taynah Pereira Galdino, Lucas Matheus da S. Oliveira et al.
Psilocybin is a molecule with significant potential for the treatment of mental disorders such as depression, anxiety, post-traumatic stress disorder, and substance abuse. In this study, it was explored the extraction of psilocybin from Psilocybe cubensis mushrooms using a factorial design approach, along with the physicochemical and phytochemical characterization of the extracted material,...
Cureus 2026 Mohsin Raza, Jasleen Kaur
Psychedelic-assisted therapies have re-emerged as a subject of increasing scientific and clinical interest in psychiatry, particularly in the context of persistent treatment gaps for conditions such as treatment-resistant depression, post-traumatic stress disorder, and substance use disorders. Compounds, including psilocybin and 3,4-methylenedioxymethamphetamine, are being evaluated in...
Advances in experimental medicine and biology 2026 Berend Olivier, Jocelien D A Olivier
Major depressive disorder (MDD), including treatment-resistant depression (TRD), is a highly prevalent psychiatric disorder. MDD is associated with severe suffering, burden and large economical costs. Although various conventional antidepressant treatments are available, a large portion of depressed people does not or not adequately respond to the first-line treatments (mostly SSRIs and SNRIs)...
Frontiers in Psychiatry 2026 Sofia Abramsky-Sze, Elliot Marseille, Richard Matzopoulos et al. correction
[This corrects the article DOI: 10.3389/fpsyt.2025.1508811.].
Frontiers in Psychiatry 2026 Sivert Drange, Jacob Cohen, Sys Stybe Johansen et al. 1 citation
Obsessive-Compulsive Disorder (OCD) can present significant challenges to individuals mental health, characterized by intrusive thoughts and repetitive maladaptive behaviors. Recent research into alternative treatments has highlighted psychedelics, notably psilocybin, for their potential therapeutic benefits in various psychiatric disorders, including OCD. This case study evaluated the impact...
Therapeutic Advances in Psychopharmacology 2026 Kristian Beichmann, Polina Catzeflis, Helena Aicher et al.
The Swiss Federal Office of Public Health provides case-by-case exemptions allowing physicians to provide psychedelic-assisted therapy (PAT) using psilocybin, lysergic acid diethylamide (LSD), or 3,4-methylenedioxy-N-methamphetamine (MDMA). The study provided an overview of PAT as currently provided in Switzerland under the regulatory framework of the Federal Office of Public Health (FOPH)....
Frontiers in Behavioral Neuroscience 2026 Dayna Forsyth, Nicoletta Faraone, Simon G. Lamarre et al.
Non-human models, including fish, are increasingly important for investigating how pharmacological agents such as hallucinogens influence behavior, physiology, and cellular processes. These models help to reveal underlying mechanisms and to support assessments of toxicological impact, efficacy, and safety. In this study, we used isogenic lineages of the amphibious mangrove rivulus (Kryptolebias...
Frontiers in Neuroscience 2026 Marcos Lago, Mariana Cerveira, Joe Xavier Simonet 1 citation
Advanced Alzheimer's disease (AD) is generally regarded as a stage of irreversible functional decline. Psilocybin is known to transiently alter large-scale brain network dynamics and to induce plasticity-related mechanisms in preclinical models, yet clinical data in advanced dementia remain lacking. We report the case of an octogenarian Japanese-American woman with a 10-year history of...